Document and Entity Information
Document and Entity Information - shares | 6 Months Ended | |
Feb. 28, 2018 | Jun. 06, 2018 | |
Document And Entity Information | ||
Entity Registrant Name | Blake Insomnia Therapeutics, Inc. | |
Entity Central Index Key | 1,556,416 | |
Document Type | 10-Q | |
Document Period End Date | Feb. 28, 2018 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --08-31 | |
Is Entity a Well-known Seasoned Issuer? | No | |
Is Entity a Voluntary Filer? | No | |
Is Entity's Reporting Status Current? | No | |
Entity Filer Category | Smaller Reporting Company | |
Entity Common Stock, Shares Outstanding | 31,597,572 | |
Document Fiscal Period Focus | Q2 | |
Document Fiscal Year Focus | 2,018 |
Balance Sheets
Balance Sheets - USD ($) | Feb. 28, 2018 | Aug. 31, 2017 |
Current Assets | ||
Cash | $ 84 | $ 84 |
Total Current Assets | 84 | 84 |
TOTAL ASSETS | 84 | 84 |
Current Liabilities | ||
Notes payable | 139,500 | 139,500 |
Accounts payable | 22,406 | 21,406 |
Due to related party | 11,637 | 11,637 |
Accrued interest | 25,981 | 19,005 |
Total Current Liabilities | 199,524 | 191,548 |
Total Liabilities | 199,524 | 191,548 |
Stockholders' Equity (Deficit) | ||
Preferred stock ($0.0001 par value; 10,000,000 authorized; no shares issued and outstanding) | ||
Common stock ($0.0001 par value, 100,000,000 shares authorized; 31,597,572 shares issued and outstanding) | 3,160 | 3,160 |
Additional paid-in capital | 217,775 | 217,775 |
Deficit accumulated during the development stage | (420,375) | (412,399) |
Total Stockholders' Equity (Deficit) | (199,440) | (191,464) |
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT) | $ 84 | $ 84 |
Balance Sheets (Parenthetical)
Balance Sheets (Parenthetical) - $ / shares | Feb. 28, 2018 | Aug. 31, 2017 |
Stockholders' Equity (Deficit) | ||
Preferred stock par value | $ 0.0001 | $ 0.0001 |
Preferred stock shares authorized | 10,000,000 | 10,000,000 |
Preferred stock shares issued | 0 | 0 |
Preferred stock shares outstanding | 0 | 0 |
Common stock par value | $ 0.0001 | $ 0.0001 |
Common stock shares authorized | 100,000,000 | 100,000,000 |
Common stock shares issued | 31,597,572 | 31,597,572 |
Common stock shares outstanding | 31,597,572 | 31,597,572 |
Statements of Operations
Statements of Operations - USD ($) | 3 Months Ended | 6 Months Ended | |||
Feb. 28, 2018 | Feb. 28, 2017 | Feb. 28, 2018 | Feb. 28, 2017 | ||
Revenues | |||||
Revenues | |||||
Operating Costs | |||||
Administrative Expenses | 500 | 20,861 | 1,000 | 42,001 | |
Total Operating Costs | 500 | 20,861 | 1,000 | 42,001 | |
Other (Expense) | |||||
Interest Expense | (3,488) | (2,738) | (6,976) | (5,254) | |
Total Other (Expense) | (3,488) | (2,738) | (6,976) | (5,254) | |
Net Loss | $ (3,988) | $ (23,599) | $ (7,976) | $ (47,255) | |
Basic loss per share | [1] | ||||
Weighted average number of common shares outstanding | 31,597,572 | 31,597,572 | 31,597,572 | 31,597,572 | |
[1] | * = Less than $ 0.01 |
Statements of Cash Flows
Statements of Cash Flows - USD ($) | 6 Months Ended | |
Feb. 28, 2018 | Feb. 28, 2017 | |
CASH FLOWS FROM OPERATING ACTIVITIES | ||
Net (loss) | $ (7,976) | $ (47,255) |
Changes in operating assets and liabilities: | ||
Increase (decrease) in accounts payable | 1,000 | 4,999 |
Increase (decrease) in accrued interest | 6,976 | 5,254 |
Net cash (used in) operating activities | (37,002) | |
CASH FLOWS FROM FINANCING ACTIVITIES | ||
Proceeds from notes paybable | 42,000 | |
Net cash provided by financing activities | 42,000 | |
Net increase (decrease) in cash | 4,998 | |
Cash at beginning of period | 84 | 4,783 |
Cash at end of period | 84 | 9,781 |
Supplemental Disclosures of Cash Flow Information: | ||
Cash paid for: Interest | ||
Cash paid for: Income Taxes |
NATURE OF OPERATIONS
NATURE OF OPERATIONS | 6 Months Ended |
Feb. 28, 2018 | |
Notes to Financial Statements | |
Note 1. NATURE OF OPERATIONS | Blake Insomnia Therapeutics Inc. (formerly Book it Local, Inc.) |
GOING CONCERN CONSIDERATION
GOING CONCERN CONSIDERATION | 6 Months Ended |
Feb. 28, 2018 | |
Notes to Financial Statements | |
Note 2. GOING CONCERN CONSIDERATION | These financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred a cumulative net loss of $420,375 since its inception and requires capital for its contemplated operation and marketing activities to take place. The Company's ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company's contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt about the Company's ability to continue as a going concern. Future issuances of the Company's equity or debt securities will be required in order for the Company to continue to finance its operations and continue as a going concern. The Company's present revenues are insufficient to meet operating expenses. The financial statements do not include any adjustments that may result from the outcome of these aforementioned uncertainties. |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 6 Months Ended |
Feb. 28, 2018 | |
Notes to Financial Statements | |
Note 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | Basis of Presentation The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars. The Companys year-end is August 31. Cash and Cash Equivalents The Company considers all highly liquid investments with original maturity of three months or less to be cash equivalents. Use of Estimates and Assumptions The preparation of financial statements in conformity with generally accepted accounting principles requires that management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. Revenue Recognition The Company applies paragraph 605-10-S99-1 of the FASB Accounting Standards Codification for revenue recognition. The Company recognizes revenue when it is realized or realizable and earned less estimated future doubtful accounts. The Company considers revenue realized or realizable and earned when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the services have been rendered and all required milestones achieved, (iii) the sales price is fixed or determinable, and (iv) collectability is reasonably assured. Foreign Currency Translation The financial statements are presented in United States dollars. In accordance with ASC 830, Foreign Currency Matters, foreign denominated monetary assets and liabilities are translated into their United States dollar equivalents using foreign exchange rates which prevailed at the balance sheet date. Revenue and expenses are translated at average rates of exchange during the year. Gains or losses resulting from foreign currency transactions are included in results of operations. Stock-Based Compensation The Company accounts for stock-based compensation using the fair value method following the guidance set forth in section 718-10 of the FASB Accounting Standards Codification for disclosure about Stock-Based Compensation. This section requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). That cost will be recognized over the period during which an employee is required to provide service in exchange for the award- the requisite service period (usually the vesting period). No compensation cost is recognized for equity instruments for which employees do not render the requisite service. Development Stage Company The Company complies with Financial Accounting Standards Codification (ASC) 915 and Securities and Exchange Commission Act Guide 7 for its characterization of the Company as development stage enterprise. Fair Value for Financial Assets and Financial Liabilities The Company follows paragraph 825-10-50-10 of the FASB Accounting Standards Codification for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB Accounting Standards Codification (Paragraph 820-10-35-37) to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value in accounting principles generally accepted in the United States of America (U.S. GAAP), and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below: Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 3 Pricing inputs that are generally observable inputs and not corroborated by market data. The carrying amounts of the Companys financial assets and liabilities, such as cash, approximate their fair values because of the short maturity of these instruments. The Company does not have any assets or liabilities measured at fair value on a recurring or a non-recurring basis, consequently, the Company did not have any fair value adjustments for assets and liabilities measured at fair value at February 28, 2018, nor gains or losses are reported in the statement of operations that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date for the period ended February 28, 2018. Income Taxes The Company follows the accrual method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on the deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. At February 28, 2018 a full deferred tax asset valuation allowance has been provided and no deferred tax asset has been recorded. Basic and Diluted Net Income (Loss) per Share The Company computes net income (loss) per share in accordance with ASC 260, "Earnings per Share" which requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of common shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period including stock options, using the treasury stock method, and convertible preferred stock, using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential common shares if their effect is anti-dilutive. Recent Accounting Pronouncements In June 2014, the FASB issued ASU 2014-10, Development Stage Entities (Topic 915) Elimination of Certain Financial Reporting Requirements. ASU 2014-10 eliminates the distinction of a development stage entity and certain related disclosure requirements., including the elimination of inception-to-date information on the statements of operations, cash flows and shareholders equity. The amendments in ASU 2014-10 will be effective prospectively for annual reporting periods beginning after December 15, 2014 and interim periods within those annual periods, however early adoption is permitted for financial statements not yet issued. The Company adopted ASU 2014-10 since the quarter ended February 28, 2015, thereby no longer presenting or disclosing any information required by Topic 915. The Company has reviewed all recently issued, but not yet effective, and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on its financial condition or the results of its operations. |
DEVELOPMENT STAGE COMPANY
DEVELOPMENT STAGE COMPANY | 6 Months Ended |
Feb. 28, 2018 | |
Notes to Financial Statements | |
Note 4. DEVELOPMENT STAGE COMPANY | The Company is in the development stage as of February 28, 2018 and to date has had no significant operations. Recovery of the Companys assets is dependent on future events, the outcome of which is indeterminable. In addition, successful completion of the Companys development program and its transition, ultimately, to attaining profitable operations is dependent upon obtaining adequate financing to fulfill its development activities and achieving a level of sales adequate to support the Companys cost structure. |
MATERIAL AGREEMENTS
MATERIAL AGREEMENTS | 6 Months Ended |
Feb. 28, 2018 | |
Notes to Financial Statements | |
Note 5. MATERIAL AGREEMENTS | On February 6, 2017, Blake Insomnia Therapeutics Inc. and Sajo Consulting LLC announced entry into a Letter of Intent to provide joint development and commercialization of Zleepax, in combination with formulations to produce a series of oral drug products to aid in the treatment of insomnia. This venture looks to develop a product to treat transient insomnia through the mechanism of Blakes proprietary formula. |
NOTES PAYABLE
NOTES PAYABLE | 6 Months Ended |
Feb. 28, 2018 | |
Notes to Financial Statements | |
Note 6. NOTES PAYABLE | On August 31, 2014 the Company issued a promissory note payable in the amount of $5,000. The note is due on August 31, 2015 and bears interest at 10% per annum. On November 20, 2014 the Company issued a promissory note payable in the amount of $10,000. The note is due on demand and bears interest at 10% per annum On January 18, 2015 the Company issued a promissory note payable in the amount of $10,000. The note is due on demand and bears interest at 10% per annum. On June 24, 2015 the Company issued a promissory note payable in the amount of $12,500. The note is due on demand and bears interest at 10% per annum. On December 10, 2015 the Company issued a promissory note payable in the amount of $15,000. The note is due on demand and bears interest at 10% per annum. On July 29, 2016 the Company issued a promissory note payable in the amount of $15,000. The note is due on demand and bears interest at 10% per annum. On September 19, 2016 the Company issued a promissory note payable in the amount of $42,000. The note is due on demand and bears interest at 10% per annum. On March 17, 2017 the Company issued a promissory note payable in the amount of $10,000. The note is due on demand and bears interest at 10% per annum. On April 19, 2017 the Company issued a promissory note payable in the amount of $20,000. The note is due on demand and bears interest at 10% per annum. The interest expense for the periods ended February 28, 2018 and February 28, 2017 is $6,976 and $5,254, respectively. |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 6 Months Ended |
Feb. 28, 2018 | |
Notes to Financial Statements | |
Note 7. RELATED PARTY TRANSACTIONS | The President of the Company provides management and office premises to the Company for no compensation. The effects of this immaterial to the financial statements taken as a whole. A shareholder of the company paid expenses on behalf of the company in the amount of $ 3,058 during the year ended August 31, 2016. During the year ended August 31, 2016, $2,522 was repaid. During the year ended August 31, 2017, a shareholder of the company paid expenses of $31,101 of expenses on behalf of the company. In June 2017, the company repaid $20,000 of expenses to the shareholder. As at February 28, 2018, there is a balance owing to the shareholder of $11,637. This balance is non-interest bearing and has no specified terms of repayment. |
STOCKHOLDERS' EQUITY
STOCKHOLDERS' EQUITY | 6 Months Ended |
Feb. 28, 2018 | |
Notes to Financial Statements | |
Note 8. STOCKHOLDERS' EQUITY | In August, 2012, the Company authorized the issue of 100,000,000 common shares of the Company at par value of $.0001and authorized the issue of 10,000,000 preferred shares at par value of $.0001. During the year ended August 31, 2014, the Company issued 21,000,000 common shares in exchange for $210,000 in services rendered, valued at the closing stock price at the date of issuance. On December 23, 2014, a former director of the Company agreed to tender 3,000,000 shares of the Company for cancellation in exchange for $10,000. In addition, the Company agreed to issue 1,500,000 shares of the Company for $5,000 cash and 1,500,000 for advisory services At February 28, 2018, there are total of 31,597,572 common shares of the Company issued and outstanding. |
SUPPLEMENTAL CASH FLOW INFORMAT
SUPPLEMENTAL CASH FLOW INFORMATION | 6 Months Ended |
Feb. 28, 2018 | |
Notes to Financial Statements | |
Note 9. SUPPLEMENTAL CASH FLOW INFORMATION | Supplemental disclosures of cash flow information for the periods ended February 28, 2018 and 2017 is summarized as follows: Cash paid during the periods ended February 28, 2018 and 2017 for interest and income taxes is as follows: 2018 2017 Interest $ - $ - Taxes $ - $ - |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 6 Months Ended |
Feb. 28, 2018 | |
Notes to Financial Statements | |
Note 10. SUBSEQUENT EVENTS | In accordance with ASC 855-10, the Company has analyzed its operations subsequent to February 28, 2018 to the date these financial statements were issued, and has determined that it does not have any material subsequent events to disclose, except as noted below. On February 1, 2018, the company entered into a consulting agreement with a former director. In consideration, the company agreed to compensate him with a 5% royalty for a period of 5 years for any revenue generated by us from sales of Zleepax and any new product or services derived from Zleepax. |
SUMMARY OF SIGNIFICANT ACCOUN16
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 6 Months Ended |
Feb. 28, 2018 | |
Summary Of Significant Accounting Policies Policies | |
Basis of Presentation | The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars. The Companys year-end is August 31. |
Cash and Cash Equivalents | The Company considers all highly liquid investments with original maturity of three months or less to be cash equivalents. |
Use of Estimates and Assumptions | The preparation of financial statements in conformity with generally accepted accounting principles requires that management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. |
Revenue Recognition | The Company applies paragraph 605-10-S99-1 of the FASB Accounting Standards Codification for revenue recognition. The Company recognizes revenue when it is realized or realizable and earned less estimated future doubtful accounts. The Company considers revenue realized or realizable and earned when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the services have been rendered and all required milestones achieved, (iii) the sales price is fixed or determinable, and (iv) collectability is reasonably assured. |
Foreign Currency Translation | The financial statements are presented in United States dollars. In accordance with ASC 830, Foreign Currency Matters, foreign denominated monetary assets and liabilities are translated into their United States dollar equivalents using foreign exchange rates which prevailed at the balance sheet date. Revenue and expenses are translated at average rates of exchange during the year. Gains or losses resulting from foreign currency transactions are included in results of operations. |
Stock-Based Compensation | The Company accounts for stock-based compensation using the fair value method following the guidance set forth in section 718-10 of the FASB Accounting Standards Codification for disclosure about Stock-Based Compensation. This section requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). That cost will be recognized over the period during which an employee is required to provide service in exchange for the award- the requisite service period (usually the vesting period). No compensation cost is recognized for equity instruments for which employees do not render the requisite service. |
Development Stage Company | The Company complies with Financial Accounting Standards Codification (ASC) 915 and Securities and Exchange Commission Act Guide 7 for its characterization of the Company as development stage enterprise. |
Fair Value for Financial Assets and Financial Liabilities | The Company follows paragraph 825-10-50-10 of the FASB Accounting Standards Codification for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB Accounting Standards Codification (Paragraph 820-10-35-37) to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value in accounting principles generally accepted in the United States of America (U.S. GAAP), and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below: Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 3 Pricing inputs that are generally observable inputs and not corroborated by market data. The carrying amounts of the Companys financial assets and liabilities, such as cash, approximate their fair values because of the short maturity of these instruments. The Company does not have any assets or liabilities measured at fair value on a recurring or a non-recurring basis, consequently, the Company did not have any fair value adjustments for assets and liabilities measured at fair value at February 28, 2018, nor gains or losses are reported in the statement of operations that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date for the period ended February 28, 2018. |
Income Taxes | The Company follows the accrual method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on the deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. At February 28, 2018 a full deferred tax asset valuation allowance has been provided and no deferred tax asset has been recorded. |
Basic and Diluted Net Income (Loss) per Share | The Company computes net income (loss) per share in accordance with ASC 260, "Earnings per Share" which requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of common shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period including stock options, using the treasury stock method, and convertible preferred stock, using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential common shares if their effect is anti-dilutive. |
Recent Accounting Pronouncements | In June 2014, the FASB issued ASU 2014-10, Development Stage Entities (Topic 915) Elimination of Certain Financial Reporting Requirements. ASU 2014-10 eliminates the distinction of a development stage entity and certain related disclosure requirements., including the elimination of inception-to-date information on the statements of operations, cash flows and shareholders equity. The amendments in ASU 2014-10 will be effective prospectively for annual reporting periods beginning after December 15, 2014 and interim periods within those annual periods, however early adoption is permitted for financial statements not yet issued. The Company adopted ASU 2014-10 since the quarter ended February 28, 2015, thereby no longer presenting or disclosing any information required by Topic 915. The Company has reviewed all recently issued, but not yet effective, and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on its financial condition or the results of its operations. |
SUPPLEMENTAL CASH FLOW INFORM17
SUPPLEMENTAL CASH FLOW INFORMATION (Tables) | 6 Months Ended |
Feb. 28, 2018 | |
Supplemental Cash Flow Information Tables | |
Cash paid during the years for interest and income taxes | 2018 2017 Interest $ - $ - Taxes $ - $ - |
NATURE OF OPERATIONS (Details N
NATURE OF OPERATIONS (Details Narrative) | 6 Months Ended |
Feb. 28, 2018 | |
Nature Of Operations Details Narrative | |
State of Incorporation | Nevada |
Date of Incorporation | Aug. 11, 2012 |
Date of Name Change | Sep. 1, 2015 |
GOING CONCERN CONSIDERATION (De
GOING CONCERN CONSIDERATION (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | 67 Months Ended | ||
Feb. 28, 2018 | Feb. 28, 2017 | Feb. 28, 2018 | Feb. 28, 2017 | Feb. 28, 2018 | |
Going Concern Consideration Details Narrative | |||||
Cumulative net loss | $ (3,988) | $ (23,599) | $ (7,976) | $ (47,255) | $ 420,375 |
NOTES PAYABLE (Details Narrativ
NOTES PAYABLE (Details Narrative) - USD ($) | 1 Months Ended | 6 Months Ended | |||||||||
Aug. 31, 2014 | Feb. 28, 2018 | Feb. 28, 2017 | Apr. 19, 2017 | Mar. 17, 2017 | Sep. 19, 2016 | Jul. 29, 2016 | Dec. 10, 2015 | Jun. 24, 2015 | Jan. 18, 2015 | Nov. 20, 2014 | |
Notes Payable Details Narrative | |||||||||||
Promissory note payable | $ 5,000 | $ 20,000 | $ 10,000 | $ 42,000 | $ 15,000 | $ 15,000 | $ 12,500 | $ 10,000 | $ 10,000 | ||
Promissory note payable, interest rate | 10.00% | 10.00% | 10.00% | 10.00% | 10.00% | 10.00% | 10.00% | 10.00% | 10.00% | ||
Promissory note payable, interest expense | $ 6,976 | $ 5,254 | |||||||||
Promissory note payable, maturity date | Aug. 31, 2015 |
RELATED PARTY TRANSACTIONS (Det
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($) | 1 Months Ended | 12 Months Ended | ||
Jun. 30, 2017 | Aug. 31, 2017 | Aug. 31, 2016 | Feb. 28, 2018 | |
Related Party Transactions Details Narrative | ||||
Due to related party | $ 11,637 | $ 11,637 | ||
Repayment of related party loan | $ 20,000 | $ 2,522 | ||
Payments made by shareholder | $ 31,101 | $ 3,058 |
STOCKHOLDERS' EQUITY (Details N
STOCKHOLDERS' EQUITY (Details Narrative) - USD ($) | 1 Months Ended | 12 Months Ended | ||||
Dec. 23, 2014 | Dec. 23, 2014 | Aug. 31, 2014 | Feb. 28, 2018 | Aug. 31, 2017 | Aug. 31, 2012 | |
Preferred stock par value | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||
Preferred stock shares authorized | 10,000,000 | 10,000,000 | 10,000,000 | |||
Common stock par value | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||
Common stock shares authorized | 100,000,000 | 100,000,000 | 100,000,000 | |||
Common stock issued for advisory services | $ 1,500,000 | |||||
Common stock shares issued | 31,597,572 | 31,597,572 | ||||
Common stock shares outstanding | 31,597,572 | 31,597,572 | ||||
Common Stock | ||||||
Common stock issued for services, Shares | 21,000,000 | |||||
Common stock issued for services, Amount | $ 210,000 | |||||
Common Stock | Former Director [Member] | ||||||
Common stock issued for cash, Shares | 1,500,000 | |||||
Common stock issued for cash, Amount | $ 5,000 | |||||
Common stock surrendered for cancellation, Shares | 3,000,000 | |||||
Common stock surrendered for cancellation, Amount | $ 10,000 |
SUPPLEMENTAL CASH FLOW INFORM23
SUPPLEMENTAL CASH FLOW INFORMATION (Details) - USD ($) | 6 Months Ended | |
Feb. 28, 2018 | Feb. 28, 2017 | |
Supplemental Cash Flow Information Details | ||
Interest | ||
Taxes |
SUBSEQUENT EVENTS (Details Narr
SUBSEQUENT EVENTS (Details Narrative) | Feb. 01, 2018 |
Subsequent Event [Member] | Consulting Agreement [Member] | Director [Member] | |
Royalty Description | The company agreed to compensate him with a 5% royalty for a period of 5 years for any revenue generated by us from sales of Zleepax and any new product or services derived from Zleepax. |